Please assess the completion status of the following clinical trial:

Trial Title: 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female, \>40 years of age~2. Reported more than 7-8 moderate to severe hot flashes per day (average) or 50-60 moderate to severe hot flashes per week for at least 30 days prior~3. Spontaneous amenorrhea for at least 12 consecutive months~4. Amenorrhea for at least 6 months and meet the biochemical criteria for menopause~5. Bilateral salpingo-oophorectomy \>6 weeks with or without hysterectomy~Exclusion Criteria:~1. BMI ≥ 40 kg/m²~2. Known non-responder to previous Selective serotonin reuptake inhibitor (SSRI) or Serotonin norepinephrine reuptake inhibitor (SNRI) treatment for VMS~3. History of self-injurious behavior~4. History of clinical diagnosis of depression; or treatment for depression~5. History of clinical diagnosis of borderline personality disorder~6. Use of an investigational study medication within 30 days prior to screening or during the study~7. Concurrent participation in another clinical trial or previous participation in this trial~8. Family of investigational-site staff

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brisdelle (paroxetine mesylate) (Type: EXPERIMENTAL): Brisdelle (paroxetine mesylate)
- Placebo capsules (Type: PLACEBO_COMPARATOR): Sugar pill

Based on this trial design, predict the completion outcome and termination type (if applicable).